Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus BEGEV as first salvage therapy for relapsed or refractory classical Hodgkin lymphoma
2024-511631-10-00Phase 2Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, vinorelbine, bendamustine and gemcitabine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoints: Dose-limiting toxicities during cycle 1 and Complete response rate after 4 induction cycles. Planned start Feb 2023; status: authorised.
02
Drugs
atezolizumabvinorelbinebendamustinegemcitabine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2024-511631-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511631-10-00.